References
- Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 1998;338:499–505.
- Chango A, Emery-Fillon N, de Courcy GP, et al A polymorphism (80G->A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Mol Genet Metab 2000;70:310–315.
- Matherly LH. Molecular and cellular biology of the human reduced folate carrier. Prog Nucleic Acid Res Mol Biol 2001;67:131–162.
- Matherly LH, Goldman DI. Membrane transport of folates. Vitam Horm 2003;66:403–456.
- Whetstine JR, Gifford AJ, Witt T, et al Single nucleotide polymorphisms in the human reduced folate carrier: characterization of a high-frequency G/A variant at position 80 and transport properties of the His(27) and Arg(27) carriers. Clin Cancer Res 2001;7:3416–3422.
- Laverdiere C, Chiasson S, Costea I, Moghrabi A, Krajinovic M. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood 2002;100:3832–3834.
- Fakhoury M. High dose MTX in pediatric acute lymphoblastic leukaemia: impact of the pharmacogenetic polymorphisms of RFC1, MDR1 and MRP2 on plasma concentration. Haematologica 2008;93(Suppl. 1):2 (Abstract 0002).
- Imanishi H, Okamura N, Yagi M, et al Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma. J Hum Genet 2007;52:166–171.
- World Health Organization. Handbook for reporting results of cancer treatment. Geneva: WHO; 1979. pp 15–22.
- National Cancer Institute Common Toxicity Criteria 2009; Available from: http://ctep.cancer.gov/reporting/ctc.html
- De Marco P, Calevo MG, Moroni A, et al Reduced folate carrier polymorphism (80A–>G) and neural tube defects. Eur J Hum Genet 2003;11:245–252.
- Kishi S, Griener J, Cheng C, et al Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol 2003;21:3084–3091.
- Assaraf YG. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Drug Resist Updat 2006;9:227–246.
- Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD. Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res 2001;61:7225–7232.
- Krajinovic M, Lamothe S, Labuda D, et al Role of MTHFR genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Blood 2004;103:252–257.